ArticleJournal of neuro-oncology2026
Spinal cord compression at initial presentation in pediatric oncology patients: neurological sequelae and survival outcomes.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Mesenchymal Chondrosarcoma Presenting as Atypical Brown-Sequard Syndrome.Annals of the Child Neurology Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
purposeSpinal cord compression (SCC) is a rare but critical oncological emergency in children and may represent the initial manifestation of an underlying malignancy. Data focusing specifically on this presentation remain limited. This study evaluated clinical characteristics, neurological outcomes, and survival in pediatric patients presenting with SCC as the initial symptom.
methodsIn this retrospective study, we included pediatric patients who presented with their first symptom of SCC between 1998 and 2020. Clinical characteristics, symptom presentation, radiologic localization, pathology, treatment, neurological outcomes, and survival were assessed. Neurological outcomes were classified as complete, partial, or none.
resultsForty patients were included, representing 2.3% of pediatric oncology cases. Median age was 8.9 years and median symptom duration was 20 days. Extramedullary–extradural lesions were most frequent (67.5%), while intramedullary localization was significantly associated with neurological sequelae. Decompressive surgery was performed in 75% of patients and was linked to a markedly lower rate of persistent sequelae (33.3% vs. 80%). Presentation beyond 28 days increased the risk of permanent neurological sequelae nearly 16-fold. Symptom duration showed strong predictive accuracy (AUC = 0.865). Overall survival varied significantly by histopathological diagnosis.
conclusionsPediatric patients who present with SCC as the initial sign of cancer are at considerable risk of long-term neurological morbidity. Disease duration and intramedullary location correlated with poor neurological outcome; the effect of decompressive surgery should be taken into account in individualized decision-making. Such results highlight the need for early detection, prompt MRI, and multidisciplinary intervention. CLINICAL
trial registrationThis study was conducted retrospectively. Therefore, clinical trial registration was not required. Clinical trial number: not applicable.
Indexed as
Identifiers
41826763What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.